#JPM22, Day 1: Bristol Myers Squibb’s blockbuster losses of exclusivity, Novartis’ spending plans and more
#JPM22, Day 1: Bristol Myers Squibb’s blockbuster losses of exclusivity, [...]
#JPM22, Day 1: Bristol Myers Squibb’s blockbuster losses of exclusivity, [...]
Catalent FDA write-up ‘allegedly’ the culprit behind Novo Nordisk’s Wegovy [...]
CEO pay for Pfizer, J&J, Moderna and AstraZeneca should be [...]
Merck’s Keytruda scores key NICE sign-off for first-line NSCLC indication [...]
FDA must hit the gas on FOIA request tied to [...]
Regeneron hands over Evkeeza rights to Ultragenyx outside US, with [...]
Fierce Pharma Asia—Samsung and Biogen rumors; Novartis-BeiGene TIGIT deal; Aduhelm’s [...]
Blueprint’s Ayvakit launch ramps up as it taps LabCorp, new [...]
Viatris shareholders rail against execs’ hefty pay packages fkansteiner Thu, [...]
Pfizer, Roche, AstraZeneca and J&J face newly revived lawsuit claiming [...]